Value proposition

World's leading digital assessment, therapy and biomarkers platform for Central Nervous System Conditions & Rare Disease

Re-imagine clinical development through digital evidence generation with Beats Medical.

Beats Medical are the world's leaders in digital assessments, therapies and biomarkers for Central Nervous System Conditions and Rare Disease.

Our patented platform technology, Colbolt, provides frictionless access to gold standard assessments and therapies in real time, with an embedded digital biomarkers focus to help our partners unlock the breakthrough therapies of the future.

Through the Beats Medical Colbolt platform, pharma partners can seamlessly integrate digital assessments and measures across the clinical development value chain, from the early stages of the R&D pipeline, to post-commercialization real world data collection. Our unique approach brings enhanced sensitivity compared to traditional measures, accuracy levels exceeding the market leading technology, and frictionless access for study participants, through a cross-platform harmonised approach with no additional hardware required.

Our embedded digital biomarker focus helps our pharma partners to understand complex CNS conditions and Rare Disease like never before, unlocking the breakthrough therapies of the future.

With a proven track record of quality, our technology is a Class 1 Medical Device, independently certified for ISO 13485 compliance for multiple years. The Colbolt platform can be rapidly customized and deployed to streamline clinical trials, enhancing your R&D efforts across all phases of your pipeline.

Ready to transform the way CNS Conditions and Rare Diseases are understood and treated forever? Visit our website, www.beatsmedical.com and schedule a demo with our team today.

Objective Digital Assessments with Enhanced Sensitivity, Individually Tailored Digital Therapies, Embedded Digital Biomarkers to Unlock Breakthrough Therapies , Central Nervous System Conditions, Rare Disease, Pharma R&D Transformation , Cross-Platform Harmonisation , Frictionless Delivery Requiring No Additional Hardware, and Patented Platform Technology, Colbolt